YS Biopharma Correlations
| YS Stock | 0.56 0.06 9.68% |
The correlation of YS Biopharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as YS Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if YS Biopharma Co moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. YS Biopharma |
The ability to find closely correlated positions to YS Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace YS Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back YS Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling YS Biopharma Co to buy it.
Moving together with YS Biopharma Stock
| + | 0.86 | JNJ | Johnson Johnson | Aggressive Push | PairCorr | |
| + | 0.78 | MRK | Merck Company | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.88 | PFE | Pfizer Inc | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.65 | SNDL | SNDL Inc | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.82 | TTOO | T2 Biosystms | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.71 | DD | Dupont De Nemours | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.85 | HD | Home Depot | Fiscal Quarter End 31st of January 2024 | PairCorr |
Moving against YS Biopharma Stock
| - | 0.59 | METROPOLIS | Metropolis Healthcare | PairCorr | ||
| - | 0.42 | MSFT | Microsoft | Fiscal Quarter End 31st of December 2023 | PairCorr |
Related Correlations Analysis
VALN | T | INTC | MMM | CVX | MSFT | MRK | CAT | HD | KO | ||
VALN | -0.19 | 0.11 | 0.81 | 0.03 | 0.1 | 0.67 | 0.43 | 0.76 | 0.7 | VALN | |
T | -0.19 | 0.67 | -0.2 | -0.8 | 0.83 | -0.63 | -0.76 | -0.3 | 0.18 | T | |
INTC | 0.11 | 0.67 | 0.26 | -0.59 | 0.87 | -0.41 | -0.3 | 0.24 | 0.32 | INTC | |
MMM | 0.81 | -0.2 | 0.26 | 0.14 | 0.09 | 0.68 | 0.56 | 0.95 | 0.84 | MMM | |
CVX | 0.03 | -0.8 | -0.59 | 0.14 | -0.84 | 0.53 | 0.84 | 0.31 | -0.21 | CVX | |
MSFT | 0.1 | 0.83 | 0.87 | 0.09 | -0.84 | -0.5 | -0.6 | 0.0 | 0.31 | MSFT | |
MRK | 0.67 | -0.63 | -0.41 | 0.68 | 0.53 | -0.5 | 0.73 | 0.68 | 0.45 | MRK | |
CAT | 0.43 | -0.76 | -0.3 | 0.56 | 0.84 | -0.6 | 0.73 | 0.7 | 0.16 | CAT | |
HD | 0.76 | -0.3 | 0.24 | 0.95 | 0.31 | 0.0 | 0.68 | 0.7 | 0.72 | HD | |
KO | 0.7 | 0.18 | 0.32 | 0.84 | -0.21 | 0.31 | 0.45 | 0.16 | 0.72 | KO | |
VALN | T | INTC | MMM | CVX | MSFT | MRK | CAT | HD | KO |
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations | High negative correlations |
Risk-Adjusted Indicators
There is a big difference between YS Biopharma Stock performing well and YS Biopharma company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze YS Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Information Ratio | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VALN | 2.00 | (0.27) | 0.00 | (0.42) | 0.00 | (0.1) | 0.00 | 4.40 | (3.90) | 13.61 | |
| T | 1.15 | 0.24 | 0.18 | 0.33 | 1.05 | 0.15 | (1.32) | 3.00 | (2.17) | 9.36 | |
| INTC | 1.59 | 0.46 | 0.21 | 0.61 | 1.70 | 0.20 | (1.74) | 3.23 | (3.07) | 11.75 | |
| MMM | 1.13 | (0.06) | 0.00 | (0.05) | 0.00 | (0.0382) | 0.00 | 2.13 | (2.32) | 7.84 | |
| CVX | 1.06 | (0.15) | 0.00 | (0.21) | 0.00 | (0.1) | 0.00 | 1.93 | (2.50) | 9.48 | |
| MSFT | 1.04 | 0.24 | 0.16 | 0.39 | 1.18 | 0.18 | (1.10) | 2.35 | (2.40) | 6.82 | |
| MRK | 0.73 | (0.11) | 0.00 | (0.32) | 0.00 | (0.12) | 0.00 | 1.36 | (1.93) | 4.82 | |
| CAT | 1.25 | (0.14) | 0.00 | (0.09) | 0.00 | (0.08) | 0.00 | 2.41 | (2.36) | 9.06 | |
| HD | 0.92 | (0.06) | 0.00 | (0.05) | 0.00 | (0.05) | 0.00 | 1.82 | (1.93) | 6.33 | |
| KO | 0.72 | (0.05) | 0.00 | (0.09) | 0.00 | (0.05) | 0.00 | 1.45 | (1.08) | 5.78 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in YS Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
Already Invested in YS Biopharma Co?
The danger of trading YS Biopharma Co is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of YS Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than YS Biopharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile YS Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for YS Biopharma Stock analysis
When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 6.524 | Quarterly Revenue Growth (0.14) | Return On Equity (0.45) |
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.